

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



DX5-1

WS 6 0855

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :	A1	(11) International Publication Number:	WO 98/22082
A61K 7/48, 38/46		(43) International Publication Date:	28 May 1998 (28.05.98)
(21) International Application Number:	PCT/IT97/00278		
(22) International Filing Date:	14 November 1997 (14.11.97)		
(30) Priority Data:	<p>RM96A000799 22 November 1996 (22.11.96) IT</p>		
(71)(72) Applicants and Inventors:	<p>CAVALIERE, widow VESELY, Renata, Maria, Anna [IT/IT]; Via Quaranta, 42, I-20139 Milano (IT). DE SIMONE, Claudio [IT/IT]; Via Nuoro, 10, I-00040 Ardea (IT).</p>		
(74) Agents:	CAVATTONI, Fabio et al.; Viale dei Parioli, 160, I-00197 Roma (IT).		
(81) Designated States:	<p>AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KP, KR, LC, LK, LR, LS, LT, LV, MG, MK, MN, MW, MX, NO, NZ, PL, RO, SD, SG, SI, SK, SL, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p>		
Published	<p><i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>		

(54) Title: SPHINGOMYELINASE COMPOSITIONS AND USE THEREOF

(57) Abstract

The use of sphingomyelinase to increase the levels of skin and mucosal ceramides, as well as dermatological and cosmetic compositions containing same which are suitable for topical application are disclosed.

no alkaline SM

topical administration

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	RS	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NB	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## SPHINGOMYELINASE COMPOSITIONS AND USE THEREOF

The present invention relates to the use of sphingomyelinase to increase the levels of skin and mucosal ceramides, and dermatological and cosmetic compositions suitable for topical application containing same.

Ceramide (N-acylsphingosine) is a lipid metabolite which has recently been proposed as an important intracellular messenger released inside the cell within a few hours of stimulation with various agents or as a result of serum deprivation, and is related to cell blockade in the G0/G1 phase and apoptosis. Ceramide is currently regarded as a second messenger in the context of the sphingomyelin signal transduction pathway. It is released by sphingomyelin as a result of the effect of sphingomyelinases, which are forms of phospholipase C specific for sphingomyelin. Inside the cells, ceramide can influence growth and differentiation, regulate protein secretion, induce DNA fragmentation and apoptosis, and increase the synthesis and secretion of cytokines. The molecular mechanisms underlying these various different actions are as yet not entirely known. More is known, on the other hand, about extracellular agonists which cause the release of ceramide. Hydrolysis of sphingomyelin occurs rapidly after exposure of the cells to exogenous sphingomyelinase or to agonists which activate endogenous sphingomyelinases. Such agonists include TNF- $\alpha$ , Fas ligand, interleukin 1- $\beta$ , IFN- $\gamma$ , 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> and NGF.

Surprisingly, we have now found that sphingomyelinase also acts as agonist in bringing about the release of ceramide into skin and mucosa.

The importance of ceramide in the skin metabolism shall be clearly apparent from what follows here below.

The main cellular constituents of the epidermis are keratinocytes, melanocytes, Langerhans cells, fibroblasts, endothelial cells and macrophages. Mono- and polymorphonuclear leukocytes can infiltrate the skin in the course of inflammation or tumours. The intracellular space, on the other hand, consists mainly of neutral lipids, glycoproteins, protein degradation products, desmosomes, active enzymes, products of sebaceous glands and ceramides. As long as this "bricks and mortar" structure is intact, the skin is endowed with both a protective layer and a selectively permeable filter.

During the differentiation process of the epidermis, which starts with cell division in the basal layers and ends with the death of keratinocytes and the development of the lipid barrier, the cells modify their lipid synthesis capability. The result is that the basal layer of the epidermis is characterized by phospholipids and cholesterol, whereas the outermost layer is characterized by cholesterol, free fatty acids, and, above all, ceramides. The lipids of the horny layer, the main component of which consists of sphingolipids, play a crucial role in maintaining the permeability barrier of the epidermis to water. The sphingolipids are extruded from the lamellar bodies of the granular cells of the epidermis. Ceramides (sphingolipids), which make up 43-46% of the horny layer, are the main polar lipids of the horny layer and play a fundamental role in the barrier function of the skin against water leakage in cell adhesion and in the differentiation of the epidermis. Literature data indicate that ceramides are synthesised *de novo* in the epidermis via phospholipid-like intermediates. They are present in fairly high concentrations in the horny layer (up to 40% of total lipids).

Like the appearance of the surface of the skin, its functional properties also undergo changes with ageing. Ageing skin is characterized by a reduced water content in the horny layer associated with reduced transdermal leakage of water. It has been shown that the ceramide 2: sphingolipid ratio decreases with age. The drop in ceramide associated with ageing may be responsible for the dehydration of the skin which is observed in the course of ageing.

In addition, abnormal ceramide levels (deficiencies) have been detected in atopic eczema, dermatosis and dermatitis, in particular atopic dermatitis, and psoriasis. Recently, an inborn deficiency of ceramide 1 has been found in autosomal recessive sphingolipidosis. Equally well known are generalised forms of sphingolipidosis such as Fabry's disease, Gaucher's disease and Tay-Sachs disease. Sjögren-Larsson syndrome is associated with a deficiency of ceramide 1 and 6 with attendant destruction of the normal skin barrier.

In the light of the foregoing, it is obviously useful to maintain high levels of ceramide in the skin. It will additionally be understood that the use of sphingomyelinase proves advantageous also at mucosal level.

There are currently available on the market numerous products containing ceramides obtained by extraction methods or synthesis and used in dermatology and cosmetics. The topical external application of ceramides is proposed for remodelling the cutaneous lipid barrier altered by ageing, drugs, detergents, physical agents, etc. Such exogenous administration does not allow for the possibility that there may be qualitative and/or quantitative variations in ceramide due to age and anatomical site, seasonal factors and diseases. Clearly, then, the exogenous administration of ceramide acts only in an additive sense (endogenous + exogenous ceramide) and not in a modulatory sense (variations in ceramide according to season, anatomical site, possible disease processes in progress, etc.).

Surprisingly, we have now found that high levels of neutral, but not acid, sphingomyelinase are present in the cells, and that sphingomyelinase is capable of inducing the generation of ceramide in the skin and mucosa.

Consequently, one object of the present invention is to provide for the use of sphingomyelinase to produce dermatological or cosmetic compositions suitable for topical application in order to increase the level of ceramides in the skin and mucosa.

According to the invention, the sphingomyelinase is preferably extracted from Gram-positive bacteria, Gram-negative bacteria, lactic bacteria or mixtures thereof. Lactic bacteria should preferably be chosen from among the following: *Lactobacillus acidophilus*, *Lactobacillus brevis*, *Lactobacillus buchneri*, *Lactobacillus casei*, *Lactobacillus catenaforme*, *Lactobacillus cellobiosus*, *Lactobacillus crispatus*, *Lactobacillus curvatus*, *Lactobacillus delbrueckii*, *Lactobacillus fermentum*, *Lactobacillus jensenii*, *Lactobacillus leichmanii*, *Lactobacillus minutus*, *Lactobacillus plantarum*, *Lactobacillus rimosae*, *Lactobacillus salivarius*, *Bifidobacterium adolescentis*, *Bifidobacterium angulatum*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium catenulatum*, *Bifidobacterium dentium*, *Bifidobacterium eriksonii*, *Bifidobacterium infantis*, *Bifidobacterium longum*, *Bifidobacterium plantarum*, *Bifidobacterium pseudocatenulatum*, *Bifidobacterium pseudolongum*, *Steptococcus lactis*, *Streptococcus raffinolactis* and *Streptococcus thermophilus*.

According to a preferred embodiment of the invention, the cells are used in the form of lyophilized or sonicated cells.

According to the present invention, the sphingomyelinase can furthermore be used as a cutaneous permeation or absorption enhancer, either alone or in admixture with other enhancers, for preparing pharmaceutical or cosmetic compositions suitable for transdermal administration.

A further object of the present invention is to provide dermatological or cosmetic compositions characterized by the fact that they contain an amount of sphingomyelinase effective for producing an increase in the level of ceramides in the skin or mucosa.

According to the invention, the sphingomyelinase contained in such compositions is preferably extracted from Gram-positive bacteria, Gram-negative bacteria, lactic bacteria or mixtures thereof. Lactic bacteria should preferably be chosen from among the following: *Lactobacillus acidophilus*, *Lactobacillus brevis*, *Lactobacillus buchneri*,

*Lactobacillus casei*, *Lactobacillus catenaforme*, *Lactobacillus cello-biosus*, *Lactobacillus crispatus*, *Lactobacillus curvatus*, *Lactobacillus delbrueckii*, *Lactobacillus fermentum*, *Lactobacillus jensenii*, *Lactobacillus leichmanii*, *Lactobacillus minutus*, *Lactobacillus plantarum*, *Lactobacillus rogosae*, *Lactobacillus salivarius*, *Bifidobacterium adolescentis*, *Bifidobacterium angulatum*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium catenulatum*, *Bifidobacterium dentium*, *Bifidobacterium eriksonii*, *Bifidobacterium infantis*, *Bifidobacterium longum*, *Bifidobacterium plantarum*, *Bifidobacterium pseudocatenulatum*, *Bifidobacterium pseudolongum*, *Streptococcus lactis*, *Streptococcus raffinolactis* and *Streptococcus thermophilus*.

According to a preferred embodiment of the invention the cells contained in the compositions are in the form of lyophilized or sonicated cells.

The dermatological or cosmetic compositions of the invention shall preferably comprise from  $1 \times 10^2$  to  $1 \times 10^{15}$  CFU of lactic bacteria per gram of composition.

The dermatological or cosmetic composition of the invention may also contain exogenous ceramide or products containing exogenous ceramide, sphingomyelines, fatty acids, cholesterol, ceramidase inhibitors, protease inhibitors, immunomodulators, vitamins, growth factors, surfactants, emulsifiers, stabilizers, lipids, rheological additives, humidifiers, antioxidants, preservatives, colouring agents, lakes, pigments, auxiliary substances (e.g. acids, bases, propellants) and functional substances (astringents, antiseborrhoeic agents, anti-dandruff agents, deodorants, skin purifiers, keratogenous agents, moisturizers, anti-xerosis agents, smoothing agents, screens, sunscreens, pigmenting agents, antidepigmenting agents, emollients, restorers, eutrophic agents, anti-wrinkle agents, antiradicals, stiffeners, anti-stretch-mark agents, vasoprotectors, anti-skin-rash agents, soothing agents, anti-cellulitis agents, tonifying agents, stimulants, hypereluting agents, epilators, nail protectors).

Lastly, the dermatological or cosmetic compositions of the invention can be formulated in the form of liquid, semiliquid, semisolid, solid or powder products, e.g. in the form of creams, ointments, lotions, capsules, pearls, ovules, mascara, eyewashes, toothpaste, mouthwashes, lipsticks, liposomes, soap, shaving soap, tonics, douches, enetroclysia solutions, shampoos, anti-dandruff preparations, impregnated and/or medicated bandage or gauze, patches, medicated emulsions, transdermal gels or patches.

To confirm the ability of these bacteria to induce the generation of ceramide in the skin, the following experiment was conducted, based on the detection of neutral sphingomyelinase, the enzyme responsible for generating ceramide in human skin.

### Methods

#### Assay of neutral and acid sphingomyelinase in lactic bacteria

10 mg of lyophilized *Streptococcus thermophilus* were resuspended in 500 µl of buffer containing HEPES 20 mM, pH 7.4, MgCl<sub>2</sub> 10 mM, EDTA 2 mM, DTT 5 mM, Na<sub>3</sub>VO<sub>4</sub> 0.1 mM, Na<sub>2</sub>MoO<sub>4</sub> 0.1 mM, p-nitrophenylphosphate 30 mM, β-glycerophosphate 10 mM, ATP 750 mM, PMSF 1 µM, leupeptin 10 µM, pepstatin 10 µM (Sigma Chemical Co.) and 0.2% Triton X-100 (for the assay of neutral SMase activity) or 500 µl of 0.2% Triton X-100 (for the assay of acid SMase activity). The samples thus prepared were then submitted to lysis by sonication (for 1 min and 50 sec, alternating 10 sec of sonication with 10 sec of rest) using Vibracell sonicator (Sonic and Materials Inc., Danbury, CT). The sonicated samples were then centrifuged for 30 min at 14,000 rpm, at 4°C, the supernatant was removed and the protein concentration determined using the Bio-Rad Laboratories kit (Richmond, CA).

100 µg of sample were incubated for 2 hours at 37°C in a buffer (50 µl final volume) containing HEPES 20 mM, MgCl<sub>2</sub> 1 mM, pH 7.4, and 2.25 µl of [N-methyl-<sup>14</sup>C]sphingomyelin (SM) (0.2 µCi/ml, a.s. 56.6 mCi/mmol, Amersham).

To measure the activity of acid sphingomyelinase, 100 µg of bacterial lysate were incubated for 2 hours at 37°C in a buffer (50 µl final volume) containing sodium acetate 250 mM, EDTA 1 mM, pH 5.0, and 2.25 µl of [N-methyl-<sup>14</sup>C]SM. The reaction was blocked by the addition of 250 µl of chloroform:methanol:acetic acid (4:2:1). The phospholipids were extracted, analysed on plates by TLC and hydrolysis of SM quantified by means of autoradiography and liquid scintillation. The SMase present in the sonicated bacteria was indicated as Units/mg protein. One unit of neutral SMase hydrolyses 1 µmole of sphingomyelin per min at pH 7.4 at 37°C. One unit of acid SMase hydrolyzes 1 nmole of SM to N-acetylsphingosine and choline phosphate per hour at pH 5.0 at 37°C.

Preparation of a cream and treatment (duration and modality)

A cream was prepared (using a dehydrating base cream) containing sonicated lactic bacteria [2 20-g tubes of base cream plus 1 vial of sonicated lactic bacteria ( $1 \times 10^{12}$  CFU) in 20 ml of water] and the effect of daily applications of the cream on the ceramide levels of the horny layer of the epidermis of the forearm was assayed in 8 volunteers as indicated in Table 1 here below.

Table 1

<u>No.</u>	<u>Sex</u>	<u>Age</u>
1	male	45
2	female	39
3	female	29
4	female	27
5	female	33
6	female	32
7	male	38
8	female	25

The subjects were instructed to self-administer the control cream and the experimental cream containing the lactic bacteria twice per day

(approximately 1 ml, morning and evening). The control cream was applied daily on the right forearm, while the experimental cream was applied on the left forearm. Both creams were rubbed in until they were fully absorbed. Lipids of the horny layer of the epidermis were collected from the forearm by washing with 250 ml of 99.5% ethanol prior to the start of application of the cream (T0) and one week (T1) after the start of treatment. The ethanol extracts were concentrated with a rotary evaporator and then evaporated dry. The dried samples were dissolved in 2 ml of chloroform, dried with nitrogen and subjected to DAG kinase assay for ceramide quantification (Amersham, Buckinghamshire, Great Britain). After three extraction runs, the lipids were dried again with nitrogen, dissolved in 100 µl of chloroform and subjected to thin layer chromatography (TLC), using chloroform: methanol:acetic acid (65:15:5, v/v/v) as the run solvent. Phosphorylated ceramide was detected by autoradiography. The patches corresponding to ceramide-1-phosphate were cut and subjected to a count of the radioactivity present using scintillation liquid in a β-counter. The amount of ceramide present was determined on the basis of a standard curve obtained with authentic ceramide (type III; of bovine brain; Sigma Chemical Co., St. Louis, MO).

### Results

#### Sphingomyelinase activity in lactic bacteria

The levels of neutral sphingomyelinase activity in the sonicated lactic bacteria samples were approximately  $2 \times 10^{-7}$  units/mg of bacteria. No acid sphingomyelinase activity was detected.

#### Effects of sonicated *Lactobacillus* on ceramide levels in the skin

The ceramide levels in the ethanol extracts obtained as described in the "Methods" section are given in Table 2 here below and the respective autoradiographs are shown in Figure 1. It can be noted, regardless of the substantial subjective basal variability, that the use of both creams gave rise to an increase in ceramide levels in the

forearm skin of all the subjects analyzed. However, the increase was much more marked and significant after application of the cream containing lactic bacteria. What is more, the effect of the experimental cream on ceramide levels could be detected earlier compared to that induced by the base cream, thus indicating faster action of the former.

Table 2

No.	Right forearm		Left forearm	
	T0	T1	T0	T1
1	0	0	0	1,941
2	223	567	147	298
3	8	500	24.2	700
4	8	347	2	300
5	300	500	435	1,390
6	400	480	236	340
7	30	28	180	270
8	10	280	12	278

Claims

1. Use of sphingomyelinase for producing dermatological and/or cosmetic compositions suitable to be topically applied, to increase the levels of skin and mucosal ceramides.
2. Use of sphingomyelinase for producing dermatological compositions suitable to be topically applied for the prevention or therapeutical treatment of atopic eczema, dermatosis and dermatitis, in particular atopic dermatitis, psoriasis, ichthyosis, Fabry's disease, Gaucher's disease, Tay-Sachs disease and Sjögren-Larsson's syndrome.
3. Use of claim 1 or 2, characterized in that the sphingomyelinase is obtained from Gram-positive bacteria, Gram-negative bacteria, lactic bacteria or mixtures thereof.
4. The use of claim 3, characterized in that the lactic bacteria are selected from the group comprising *Lactobacillus acidophilus*, *Lactobacillus brevis*, *Lactobacillus buchneri*, *Lactobacillus casei*, *Lactobacillus catenaforme*, *Lactobacillus cellobiosus*, *Lactobacillus crispatus*, *Lactobacillus curvatus*, *Lactobacillus delbrueckii*, *Lactobacillus fermentum*, *Lactobacillus jensenii*, *Lactobacillus leichmanii*, *Lactobacillus minutus*, *Lactobacillus plantarum*, *Lactobacillus rimosae*, *Lactobacillus salivarius*, *Bifidobacterium adolescentis*, *Bifidobacterium angulatum*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium catenulatum*, *Bifidobacterium dentium*, *Bifidobacterium eriksonii*, *Bifidobacterium infantis*, *Bifidobacterium longum*, *Bifidobacterium plantarum*, *Bifidobacterium pseudocatenulatum*, *Bifidobacterium pseudolongum*, *Streptococcus lactis*, *Streptococcus raffinolactis* and *Streptococcus thermophilus*.
5. Use of sphingomyelinase as cutaneous permeation or absorption enhancer for preparing pharmaceutical or cosmetic compositions suitable for transdermal administration.

6. The use of any of the preceding claims, characterized in that sphingomyelinase is used in the form of lyophilized or sonicated cells.

7. A dermatological or cosmetic composition characterized in that it comprises an amount of sphingomyelinase effective for bringing about an increase in the level of skin and mucosal ceramides.

8. The composition of claim 7, characterized in that the sphingomyelinase is obtained from Gram-positive bacteria, Gram-negative bacteria, lactic bacteria or mixtures thereof.

9. The composition of claim 8, characterized in that the lactic bacteria are selected from the group comprising *Lactobacillus acidophilus*, *Lactobacillus brevis*, *Lactobacillus buchneri*, *Lactobacillus casei*, *Lactobacillus catenaforme*, *Lactobacillus cellobiosus*, *Lactobacillus crispatus*, *Lactobacillus curvatus*, *Lactobacillus delbrueckii*, *Lactobacillus fermentum*, *Lactobacillus jensenii*, *Lactobacillus leichmanii*, *Lactobacillus minutus*, *Lactobacillus plantarum*, *Lactobacillus rogosae*, *Lactobacillus salivarius*, *Bifidobacterium adolescentis*, *Bifidobacterium angulatum*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium catenulatum*, *Bifidobacterium dentium*, *Bifidobacterium eriksonii*, *Bifidobacterium infantis*, *Bifidobacterium longum*, *Bifidobacterium plantarum*, *Bifidobacterium pseudocatenulatum*, *Bifidobacterium pseudolongum*, *Streptococcus lactis*, *Streptococcus raffinolactis* and *Streptococcus thermophilus*.

10. The composition of claims 7, 8 or 9, characterized in that sphingomyelinase is in the form of lyophilized or sonicated cells.

11. The composition of any one of claims 7-10, characterized in that it comprises from  $1 \times 10^2$  to  $1 \times 10^{15}$  lactic bacteria/gram of composition.

12. The composition of any one of claims 7-11, characterized in that it further comprises exogenous ceramide or products containing exogenous ceramide, sphingomyelines, fatty acids, cholesterol,

ceramidase inhibitors, protease inhibitors, immunomodulators, vitamins, growth factors, surfactants, emulsifiers, stabilisers, lipids, rheological additives, humidifiers, antioxidants, preservatives, colouring agents, lakes, pigments, auxiliary substances (e.g. acids, bases, propellants) and functional substances (astringents, antiseborrhoeic agents, anti-dandruff agents, deodorants, skin purifiers, keratogenous agents, moisturisers, anti-xerosis agents, smoothing agents, screens, sunscreens, pigmenting agents, anti-depigmenting agents, emollients, restores, eutrophic agents, anti-wrinkle agents, antiradicals, stiffeners, anti-stretch-mark agents, vasoprotectors, anti-skin-rash agents, soothing agents, anti-cellulitis agents, tonifying agents, stimulants, hypereluting agents, epilators, nail protectors).

13. The composition of any one of claims 7-12 in the form of creams, ointments, lotions, capsules, pearls, ovules, mascara, eyewashes, toothpaste, mouthwashes, lipsticks, liposomes, soap, shaving soap, tonics, douches, enteroclysis solutions, shampoos, anti-dandruff preparations, impregnated and/or medicated bandage or gauze, patches, medicated emulsions, transdermal gels or patches.

1/1




FIG. 1

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 97/00278

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 6 A61K7/48 A61K38/46

According to International Patent Classification(IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 13, no. 3 (C-557) '3351! , 1989 & JP 63 216813 A (NOEBIA K.K.) see abstract	1-13
A	FR 2 729 079 A (SEDERMA SA) 12 July 1996	1

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

1

Date of the actual completion of the international search	Date of mailing of the international search report
19 March 1998	26/03/1998
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Glikman, J-F

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Inte onal Application No

PCT/IT 97/00278

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2729079 A	12-07-96	NONE	